Boji Medical approves cash management plan, amends company rules

Guangzhou Boji Medical & Biotechnological held its Fifth Board of Directors' Seventeenth Meeting and Fifth Supervisory Board's Sixteenth Meeting on September 12, 2025. Both meetings approved the use of temporarily idle funds for cash management, with a maximum allocation of RMB 250 million. This aims to increase company returns without impacting normal operations, with funds rolling over for 12 months.

The company also convened its First Extraordinary General Meeting for 2025 on September 12, 2025. Key resolutions passed included amendments to the company's registered capital and articles of association, shareholder meeting rules, board of directors' meeting rules, shareholder meeting voting management system, independent director work rules, external investment management system, external guarantee management system, related party transaction management system, fundraising management system, and accounting firm selection system. The company also approved the 2026-2028 shareholder return plan.

GF Securities, acting as the continuous supervision institution, has issued its positive verification opinion, noting that the cash management and all other resolutions are in compliance with regulations and serve the interests of the company and its shareholders. The company confirmed that all resolutions were passed legally and effectively.